MAIA Biotechnology, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for MAIA, updated each market day.
MAIA AI Sentiment
AI sees no strong directional signal for MAIA Biotechnology, Inc. stock over the next 10 market days.
Prediction date: April 10, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About MAIA Biotechnology, Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.
Sector
Exchange
Market Cap
$72,805,789
Cap Tier
Employees
13
Headquarters
CHICAGO, IL
Listed Since
July 28, 2022
Website
MAIA Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
MAIA Volatility
MAIA Biotechnology, Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
